ASX:BDX

BCAL Diagnostics (BDX) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BDX stock logo

About BCAL Diagnostics Stock (ASX:BDX)

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

BDX Stock News Headlines

His win rate puts Warren Buffett to shame…
Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.
Southern Calif Bancorp BCAL
BCAL Diagnostics Limited (BDX.XA)
Becton Dickinson (BDX) Receives a Buy from DBS
BCAL Diagnostics Ltd (BDX)
Southern California Bancorp (BCAL)
His win rate puts Warren Buffett to shame…
Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.
BCAL Findings Presented at 2023 ASCO Annual Meeting
BDX.N
BCAL Diagnostics Limited (BDX.AX)
See More Headlines
Receive BDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BCAL Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
72,000
Year Founded
N/A

Profitability

Net Income
$-5,000,000.00
Net Margins
-134.82%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.71 million
Book Value
A$0.02 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.21
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Ms. Jayne Andrea Shaw
    Co-Founder & Executive Chairman
  • Dr. John G. Hurrell B.Sc
    Fulbright Fel, M.Sc(Qual), Ph.D., Chief Executive Officer
  • Hon. Ronald Anthony Phillips A.O.
    Co-Founder & Non-Executive Director
  • Dr. Amani Batarseh Ph.D.
    Chief Scientist Officer
  • Mr. Guy Adrian Robertson B.Com. (Age 71)
    B.Comm(Hons.), CA, MAICD, CFO & Company Secretary
  • Mr. Shane Ryan M.B.A.
    Chief Operating Officer
  • Sean Kennedy
    Director of Corporate Finance

This page (ASX:BDX) was last updated on 4/29/2024 by MarketBeat.com Staff

From Our Partners